Calquence Approved to Treat CLL, SLL

FRIDAY, Nov. 22, 2019 -- The U.S. Food and Drug Administration has granted supplemental approval to Calquence (acalabrutinib) for treatment of chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL), the agency announced...
Source: Drugs.com - Daily MedNews - Category: General Medicine Source Type: news